Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Common Equity (2016 - 2025)

Historic Common Equity for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $9.2 million.

  • Ultragenyx Pharmaceutical's Common Equity fell 9735.92% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.2 million, marking a year-over-year decrease of 9735.92%. This contributed to the annual value of $255.3 million for FY2024, which is 730.43% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Common Equity stood at $9.2 million for Q3 2025, which was down 9735.92% from $151.3 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Common Equity registered a high of $1.1 billion during Q1 2021, and its lowest value of $9.2 million during Q3 2025.
  • For the 5-year period, Ultragenyx Pharmaceutical's Common Equity averaged around $437.6 million, with its median value being $346.8 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 99360.85% in 2024, then crashed by 9735.92% in 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Common Equity (Quarter) stood at $922.6 million in 2021, then tumbled by 61.79% to $352.5 million in 2022, then fell by 21.87% to $275.4 million in 2023, then dropped by 7.3% to $255.3 million in 2024, then tumbled by 96.41% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $151.3 million for Q2 2025, and $144.2 million during Q1 2025.